Likewise, serous carcinomas presenting without metastatic disease at diagnosis displayed a positive immunoreactivity for HDAC-4 more frequently (86.8% vs. 66.7% for cases with metastatic disease, Chi-square test, p = 0.05), which was an association of marginal significance when the analysis was performed on the entire cohort (p = 0.097). Here, HDAC4 is linked to serous adenocarcinoma.